Scienture Secures Key Patent for REZENOPY™ Naloxone Spray, Extending IP Protection Through 2041
SCNX sits 66% above its 52-week low of $0.238 on light trading volume (0.2× avg).
Summary
Scienture Holdings has been granted a U.S. patent for its REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, securing intellectual property protection for the product until 2041. This patent significantly strengthens the long-term value of REZENOPY™, which is the highest FDA-approved dose of naloxone nasal spray and targets the approximately $141 million annual U.S. naloxone market. This positive news arrives as the company faces severe financial distress, including a 'going concern' warning, substantial losses, and a recent CFO resignation. The extended IP protection is crucial for the micro-cap company, providing a long runway for potential revenue generation and enhancing the product's attractiveness for future partnerships or financing. The planned commercial launch of REZENOPY™ in mid-July will be critical for the company's immediate revenue generation.
At the time of this announcement, SCNX was trading at $0.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.1M. The 52-week trading range was $0.24 to $2.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.